Pharmaceutical Products / Drugs Technology Offers

Technology Categories

By Type

Consejo Superior de Investigaciones Científicas posted this:

Antibiotics to treat diseases caused by Helicobacter CSIC, the University of Zaragoza, Institute Pasteur, IISA and ARAID have developed chemical derivatives that act selectively against the bacterium Helicobacter pylori, managing to reduce the bacterial load and even eradicate gastric infections caused by it. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Antibiotics to treat diseases caused by Helicobacter

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

New compound to successfully treat degenerative diseases of the retina The research group "Neurobiología del sistema visual y terapia de enfermedades neurodegenerativas" of the University of Alicante has discovered the use of the compound 3-(2-isothiocyanatethyl)-5-methoxy-1H-indol, and its pharmaceutically acceptable salts, for the preventive or therapeutic treatment of degenerative diseases of the retina, such as: pigmentary retinosis, diabetic retinopathy, glaucoma or age-related macular degeneration. This compound has demonstrated, in vitro and in vivo, its neuroprotective capacity in various models under laboratory conditions. This compound is characterized by a 20% increase in neuronal survival, a 35% increase in visual acuity, and a 15% increase in contrast sensitivity. Therefore, it has very promising properties that could position it as the first effective treatment against degenerative diseases of the retina. We are looking for companies interested in acquiring this patent for commercial exploitation.

New compound to successfully treat degenerative diseases of the retina

IDIBELL posted this:

Drug repurposing for lupus nephritis therapy Drug repurposing for lupus nephritis therapy. Compound X, already approved for human use in other medical indications, administered orally, can be repurposed for lupus nephritis treatment. The principal goal of compound X therapy in lupus nephritis is to normalize renal function or, at least, to prevent the progressive loss of renal function. ✓ Less side effects than the standard of care ✓ Already approved for human in other medical indications (Reprofiling) ✓ Market with 1 approval in last 50 years

Drug repurposing for lupus nephritis therapy

Centre Technology Transfer CITTRU posted this:

A new method of the stereoselective synthesis of chosen medicines The subject of the offer is a new method of an asymmetric reduction of prochiral ketones and imines used in the synthesis of commonly used medicines, e.g. hormonal (eg. Cincalcet), pulmonary (eg. Salbutamol) and neurological ones (eg. Rasagiline).

A new method of the stereoselective synthesis of chosen medicines

uacoopera posted this:
Licensing Manager at uacoopera

Electrospinning system for large-scale manufacturing of aligned 3D fiber matrices Continuous electrospinning system and process for production of thick 3D matrices of aligned polymeric fibers. The matrices obtained with this technology can have aligned polymeric fibers with several patterns along the matrix’s thickness, which size depends solely on the number of layers of deposited fibers, on the fibers thickness and the compaction degree between layers. In this way, the present technology can be applied in varied areas, for the manufacture of products or structures, at the nanometric scale, that depend on high surface areas, such as biotechnology, pharmaceutics and tissue engineering.

Electrospinning system for large-scale manufacturing of aligned 3D fiber matrices

uacoopera posted this:
Licensing Manager at uacoopera

LipidPro - Fluorescent dye for detection of lipid aggregates in living cells and other samples Family of dyes to be used in fluorescence microscopy imaging of cells in culture or entire organisms, including live cell imaging. The fluorophores are not toxic, and preferentially bind to lipid aggregates, such as intracellular lipid droplets. They also light up cells by binding weakly to several subcellular structures. Importantly, the fluorophores change color with the polarity of the environment and may be used to initially characterize alterations in organelle polarity. The most promising fluorophore, LipidPro, has been tested in fibroblast-based High Throughput Screens for the diagnosis of Faber’s disease.

LipidPro - Fluorescent dye for detection of lipid aggregates in living cells and other samples

Eva Gabaldon posted this:
Licensing Manager at Spanish National Research Council

Efavirenz use for Niemann-Pick C treatment CSIC has developed and brought to preclinical stage a novel non-invasive pharmacological treatment for Niemann Pick disease Type C (NPC) and other lysosomal storage disorders where cholesterol accumulates in the brain.

Efavirenz use for Niemann-Pick C treatment

uacoopera posted this:
Licensing Manager at uacoopera

Magnetic nanoparticles for selective enrichment of proteins in complex mixtures New method for preparing ion chelating magnetic nanoparticles, which allow selective protein enrichment, namely metalloproteases (MMPs) and His-tagged proteins, from complex mixtures.

Magnetic nanoparticles for selective enrichment of proteins in complex mixtures

Universidad de Alcalá-OTRI posted this:

Compounds for the treatment of Leishmania infections The research group Heterobetainas of the University of Alcalá presents the preparation and uses of a series of compounds that act as bioactive agents against the Leishmania parasite and as therapeutic agents in the treatment of this disease, in both, its visceral (LV) version and in the mucocutaneous one (CML). The group is looking for pharmaceutical companies interested in manufacturing an active ingredient for the formulation of a leishmanicidal drug based on these compounds. The group proposes the signing of a patent license agreement, a collaboration agreement or a commercial agreement with technical

Compounds for the treatment of Leishmania infections

Unitat de Valorització i Transferència Tecnològica (UViT) posted this:
Technology Transfer Office at Universitat de Lleida

New therapeutic candidate for Spinal Muscular Atrophy We are looking for a licensing agreement with a company with expertise in the field of neurosciences. More particularly, we are willing to find a company involved in the development of therapeutic solutions for the rare disease Spinal Muscular Atrophy (SMA).

Aia Malik posted this:
Commercial Development Manager at Lucideon

iCRT - a novel encapsulation and controlled release platform iCRT is a novel and proprietary platform developed in the UK - the platform was designed to tackle difficult actives and complex formulations. It uses inorganic materials to overcome the challenges experienced when using polymeric delivery systems.

iCRT - a novel encapsulation and controlled release platform

uacoopera posted this:
Licensing Manager at uacoopera

Innovative methodology for nanoencapsulation of montelukast in cyclodextrin Cyclodextrin is a nano-sized capsule that allows increasing the stability and aqueous solubility of active pharmaceutical ingredients such as montelukast. This technology comprehends an alternative method to obtain an amorphous solid composed by montelukast and cyclodextrin. In alternative to conventional methodologies, this method allows the encapsulation to occur without requiring the use of solvents and the formation of degradation products.

Innovative methodology for nanoencapsulation of montelukast in cyclodextrin

Universidad de Granada posted this:

Method for isolating circulating epithelial pulmonary cells and their use as markers for diagnosing Chronic Obstructive Pulmonary Disease (COPD)A procedure is described based on Liquid Biopsy techniques that allows both the diagnosis of COPD, as well as its evolution in patients. In order to do that, circulating pulmonary cells (CPCs) that could be present in blood of patients diagnosed with COPD are detected and characterized by combining two different techniques: - Immunogenetic positive selection for their isolation in peripheral blood. - Immunocytochemistry for detecting CPCs by using specific markers for pulmonary epithelial cells.

Method for isolating circulating epithelial pulmonary cells and their use as markers for diagnosing Chronic Obstructive Pulmonary Disease (COPD)

Russell Nicholls posted this:
Licensing Manager at Curtin University

Rhenium compounds as anticancer agents Metal-based anticancer agents, such as cisplatin, are used as gold standard cancer therapies. While these drugs are effective in eradicating malignant cells, their selectivity is poor, meaning that significant adverse effects are experienced during treatment through damage inflicted on healthy cells. Improved selectivity and targeted cancer therapies with minimal side effects are being sought. Many drugs have been developed which contain platinum, and other metals are now being developed as anticancer agents. Researchers at Curtin University developed a series of rhenium containing compounds that target cancerous cells and block their growth. These compounds are promising candidates for treatment of tumours with aggressive potential for metastasis (for example, pancreatic cancer). A library of molecular candidates have been synthesized, and structure-activity relationship to modulate selectivity and therapeutic potential has been explored.

Universidad de Alcalá-OTRI posted this:

Derivatives of Indolin-2-one and its therapeutic use in inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer diseases.The research group of “Neuroendocrinology of the cannabinoid / vanilloid system” of the University of Alcalá, in collaboration with researchers from the Institute of Medical Chemistry of CSIC, have developed a series of compounds derived from indolin-2-one, emphasizing the pharmaceutical compositions containing in the compounds and their use for the treatment of diseases mediated by AMPK (AMP-activated kinase), particularly inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer. The group is looking for companies in the pharmaceutical and health sector with the objective of reaching technical cooperation agreements, commercial agreements with technical assistance or patent licensing.

Derivatives of Indolin-2-one and its therapeutic use in inflammatory, autoimmune, metabolic, cardiovascular, neurological and cancer diseases.

1
2
3
4
5